FGFR3 mutations in prostate cancer: Association with low-grade tumors

Modern Pathology

Volumn 22, Issue 6, 2009, Pages 848-856

  Hernández, Silvia ^a   De Muga, Silvia ^b,c   Agell, Laia ^b,c   Juanpere, Nuria ^b,c   Esgueva, Raquel ^b,c   Lorente, José A ^b,c   Mojal, Sergi ^b   Serrano, Sergio ^b,c   Lloreta, Josep ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Bladder cancer; FGFR3; Mutation; Prostate cancer; Skin tumors

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ARTICLE; AUTOPSY; BLADDER TUMOR; CONTROLLED STUDY; EXON; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISSENSE MUTATION; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE TUMOR; RECEPTOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TUMOR; TUMOR BIOPSY; UROGENITAL TRACT TUMOR;

COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SKIN NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 67349105009     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.46     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Woolf SH. Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 1995;33:1401-1405.
3. Thomson A. Role of androgens and fibroblast growth factors in prostatic development. Reproduction 2001;121:187-195.
4. Lin Y, Liu G, Zhang Y, et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 2007;134:723-734.
5. Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. Differentiation 2007;75: 638-651.
6. Jin C, McKeehan K, Guo W, et al. Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. Cancer Res 2003;63:8784-8790.
7. Jin C, Wang F, Wu X, et al. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 2004;64:4555-4562.
8. Wu X, Jin C, Wang F, et al. Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors. Cancer Res 2003;63:4936-4944.
9. Heer R, Douglas D, Mathers ME, et al. Fibroblast growth factor 17 is over-expressed in human prostate cancer. J Pathol 2004;204:578-586.
10. Ropiquet F, Giri D, Kwabi-Addo B, et al. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res 2000;60:4245-4250.
11. Tanaka A, Furuya A, Yamasaki M, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res 1998;58:2053-2056.
12. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-197.
13. Shaoul E, Reich-Slotky R, Berman B, et al. Fibroblast growth factor receptors display both common and distinct signaling pathways. Oncogene 1995;10: 1553-1561.
14. Winter SF, Acevedo VD, Gangula RD, et al. Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene 2007;26:4897-4907.
15. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res 1999;5:1063-1071.
16. Valve EM, Nevalainen MT, Nurmi MJ, et al. Increased expression of FGF-8 isoforms and FGF receptors in human premalignant prostatic intraepithelial neopla-sia lesions and prostate cancer. Lab Invest 2001;81: 815-826.
17. Sahadevan K, Darby S, Leung HY, et al. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007;213:82-90.
18. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-327.
19. Fritzsche S, Kenzelmann M, Hoffmann MJ, et al. Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 2006;13: 839-849.
20. Kwabi-Addo B, Wang J, Erdem H, et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res 2004;64:4728-4735.
21. McKie AB, Douglas DA, Olijslagers SY, et al. Epige-netic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005;24: 2166-2174.
22. Horton WA, Lunstrum GP. Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism. Rev Endocr Metab Disord 2002;3: 381-385.
23. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002;16:1446-1465.
24. Ornitz DM. FGF signaling in the developing endo-chondral skeleton. Cytokine Growth Factor Rev 2005;16:205-213.
25. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
26. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene 2001;20:4416-4418.
27. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158: 1955-1959.
28. Hernandez S, Lopez-Knowles E, Lloreta J, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005;11: 5444-5450.
29. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664-3671.
30. Logie A, Dunois-Larde C, Rosty C, et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005;14:1153-1160.
31. Hafner C, Vogt T, Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 2006;5:2723-2728.
32. Hernandez S, Toll A, Baselga E, et al. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol 2007;127:1664-1666.
33. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541-3543.
34. Naimi B, Latil A, Berthon P, et al. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/ S249C mutations in human prostate cancer. Int J Cancer 2000;87:455-456.
35. Knowles MA. Role of FGFR3 in urotelial cell carcinoma: biomarker and potencial therapeutic target. World J Urol 2007;25:581-593.
36. Hafner C, Hartmann A, van Oers JM, et al. FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization. Mod Pathol 2007;20:895-903.
37. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-1921.
38. Damber JE, Aus G. Prostate cancer. Lancet 2008;371:1710-1721.
39. Reynolds MA, Kastury K, Groskopf J, et al. Molecular markers for prostate cancer. Cancer Lett 2007;249: 5-13.
40. Kopper L, Tímár J. Genomics of prostate cancer: is there anything to 'translate'? Pathol Oncol Res 2005; 11:197-203.
41. Hafner C, Hartmann A, Vogt T. FGFR3 mutations in epidermal nevi and seborrheic keratoses: lessons from Urothelium and skin. J Invest Dermatol 2007;127:1572-1573.
42. Toll A, Real F. Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle 2008;7:2674-2681.
43. Christian Hafner C, van Oers JM, Vogt T, et al. Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006;116: 2201-2207.
44. Hafner C, López-Knowles E, Nuno ML, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 2007;104: 13450-13454.
45. Hafner C, van Oers JM, Hartmann A, et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006;126:2404-2407.
46. Bernard-Pierrot I, Brams A, Dunois-Lardé C, et al. Oncogenic properties of the mutated forms of fibro-blast growth factor receptor 3b. Carcinogenesis 2006;27:740-747.
47. Li E, You M, Hristova K. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol 2006;356:600-612.